Suppr超能文献

肾细胞癌合并冯·希佩尔-林道病患者的肾移植

Renal transplantation in patients with renal cell carcinoma and von Hippel-Lindau disease.

作者信息

Steinbach F, Novick A C, Shoskes D

机构信息

Department of Urology, Cleveland Clinic Foundation, Ohio.

出版信息

Urology. 1994 Nov;44(5):760-3. doi: 10.1016/s0090-4295(94)80224-6.

Abstract

This study reviewed the management and outcome of patients with von Hippel-Lindau disease (VHLD) who underwent renal transplantation after being rendered anephric to treat multifocal bilateral renal cell carcinoma (RCC). Five patients with bilateral RCC and VHLD underwent renal transplantation at our hospital. Initial treatment of RCC consisted of bilateral nephrectomy in 2 patients and unilateral nephron-sparing surgery with contralateral nephrectomy in 3 patients. All of the latter 3 patients experienced isolated tumor recurrence in the renal remnant at 48, 64, and 66 months postoperatively; this was managed by complete excision of the renal remnant. Renal transplantation was performed 11 to 24 months after initiation of dialysis. Postoperatively, all of the allografts functioned well with no further requirement for dialysis. Currently, 4 patients are alive at a mean post-transplant follow-up interval of 26 months (range, 7 to 66 months) with excellent graft function and no evidence of malignancy. One patient died 17 months following transplantation due to metastatic disease. Renal transplantation can provide satisfactory replacement therapy for patients with end-stage renal disease with VHLD and treated RCC.

摘要

本研究回顾了因双侧多发性肾细胞癌(RCC)而无肾后接受肾移植的希佩尔-林道病(VHLD)患者的治疗及预后情况。5例双侧RCC合并VHLD患者在我院接受了肾移植。RCC的初始治疗包括2例行双侧肾切除术,3例行单侧保留肾单位手术并对侧肾切除术。后3例患者术后48、64和66个月均在肾残余处出现孤立性肿瘤复发,通过完整切除肾残余进行处理。在开始透析11至24个月后进行肾移植。术后,所有移植肾均功能良好,无需进一步透析。目前,4例患者存活,移植后平均随访间隔26个月(范围7至66个月),移植肾功能良好,无恶性肿瘤证据。1例患者在移植后17个月因转移性疾病死亡。肾移植可为终末期肾病合并VHLD且已治疗RCC的患者提供满意的替代治疗。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验